Amicus abandons wound treatment, focus shifts to future trial data

Print pagePDF pageEmail page

(Reuters) – Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors appeared to focus on the drug developer’s expanding pipeline.


Reuters: Health News … More ادامه مطلب

Leave a Reply

Time limit is exhausted. Please reload CAPTCHA.